Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). RESULTS: In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. CONCLUSIONS: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, IL-1RA-blocking Ab (anakinra) and IL-1β-blocking Ab (canakinumab) are already FDA approved as anti-inflammatory biologics for the treatment of rheumatoid arthritis (130) and NLRP3-inflammasome-mediated cryopyrin-associated periodic syndrome (CAPS) (131), respectively.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [131]
Citations
Cites
Natural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,032
Self-citationSpectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Self-citationHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577 · cited 2×
“Viral infection 0 2 (13) 0 0 Headache 0 2 (13) 0 3 ( 10 )”
URTICARIA, DEAFNESS, AND AMYLOIDOSIS: A NEW HEREDO-FAMILIAL SYNDROME
(1962) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a066967 · Cited by 372
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Self-citationPrimer: inflammasomes and interleukin 1β in inflammatory disorders
Church, L. D., Cook, G. P., & McDermott, M. F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0681 · Cited by 309
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044941 · Cited by 225
Leslie, K. S., Lachmann, H. J., Bruning, E., McGrath, J. A., Bybee, A., Gallimore, J. R., Roberts, P. F., Woo, P., Grattan, C. E., & Hawkins, P. N. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.12.1591 · Cited by 186 · cited 13×
“Rhinitis 4 (11) 1 (7) 2 (12) 0 Bronchitis 3 (9) 1 ( 7 ) 1 (6) 0”
InfluentialSelf-citationAlten, R., Gram, H., Joosten, L. A., Berg, W. B. V. D., Sieper, J., Wassenberg, S., Burmester, G., van Riel, P., Diaz-Lorente, M., Bruin, G. J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2438 · Cited by 170
The many worlds of reducing interleukin‐1
Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21107 · Cited by 104
Research works printed but not linked: 5
- Muckle TJ, 1962, Q J Med, 31, 235
- Lachmann HJ, 2008, Clin Exp Rheumatol, 26, 181
- Kuemmerle-Deschner JB, 2008, Clin Exp Rheumatol, 26, 180
- Kummerle-Deschner J, 2008, Ann Rheum Dis, 67, 104
- Maier J, 2008, J Rheumatol, 35, 939
Cited by
Items 401–500 of 869
The concept of the inflammasome and its rheumatologic implications
So, A. K.-L., & Busso, N. (2014) · Joint Bone Spine · doi:10.1016/j.jbspin.2014.02.009 · Cited by 22
Role of biologics in intractable urticaria
Cooke, A., Bulkhi, A. A., & Casale, T. B. (2015) · Biologics · doi:10.2147/btt.s63839 · Cited by 24
Sjöwall, C., Kastbom, A., Almroth, G., Wetterö, J., & Skogh, T. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.100690 · Cited by 22
“In other instances, therapy targeting cytokines or cytokine-receptors can efficiently halt the progression of autoimmune or autoinflammatory diseases, as illustrated by antibodies to tumor necrosis factor (TNF) or interleukin- (IL-) 6 receptor in rheumatoid arthritis (RA), and IL-1 targeting therapies in cryopyrin ass…”
BackgroundWorking the endless puzzle of hereditary autoinflammatory disorders
Caso, F., Cantarini, L., Lucherini, O. M., Sfriso, P., Fioretti, M., Costa, L., Vitale, A., Atteno, M., Galeazzi, M., Muscari, I., et al. (2013) · Modern Rheumatology · doi:10.3109/14397595.2013.843755 · Cited by 24
RIPK1-Associated Inborn Errors of Innate Immunity
Zhang, J., Jin, T., Aksentijevich, I. A., & Zhou, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.676946 · Cited by 27
“Although cytokine inhibit ion is effect ive in many autoinflammatory diseases, such as anti-IL-1b therapies for most inflammasomopathies (55, 56), TNF inhibitors for NFkB-activation disorders (57, 58), and JAK inhibitors for interferonopathies (59), concerns remain on the long-term use and efficacy of biological thera…”
BackgroundSuccessful treatment with canakinumab of a paediatric patient with resistant Behçet’s disease
Pagnini, I., Bondi, T., Simonini, G., Giani, T., Marino, A., & Cimaz, R. (2015) · Rheumatology · doi:10.1093/rheumatology/kev197 · Cited by 21
Maródi, L., & Casanova, J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.009 · Cited by 21
“IL-1 blockade and primary defects of the IL-1 receptor–associated kinase pathway Human anti-IL-1b mAb has been approved for use in the treatment of cryopyrin-associated periodic syndrome and Muckle-Wells syndrome.(64) IL-1 can also be inhibited by treatment with anakinra, a soluble recombinant IL-1 receptor (IL1R; Fig…”
Periodic fever syndromes and the autoinflammatory diseases (AIDs)
Marino, A., Tirelli, F., Giani, T., & Cimaz, R. (2019) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2019.100031 · Cited by 21
Targeting of the innate immunity/inflammation as complementary anti-tumor therapies
Germano, G., Mantovani, A., & Allavena, P. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.595732 · Cited by 21
Ocular manifestations of the autoinflammatory syndromes
Tarabishy, A. B., Hise, A. G., & Traboulsi, E. I. (2012) · Ophthalmic Genetics · doi:10.3109/13816810.2012.695421 · Cited by 22
Challenges in Diagnosing Muckle‐Wells Syndrome: Identifying Two Distinct Phenotypes
Kuemmerle-Deschner, J. B., Samba, S. D., Tyrrell, P. N., Koné‐Paut, I., Marie, I., Deschner, N., & Benseler, S. M. (2013) · Arthritis Care & Research · doi:10.1002/acr.22206 · Cited by 21
“of subspecialties seen per patient 2 (2–5) 2 (2–5) 2 (2–5) Annual health care provider visits prior to diagnosis of MWS None 9 (26) 3 (23) 6 (28) NS 1 visit 2 (6) 0 (0) 2 (10) NS 2–4 visits 10 (29) 2 (15) 8 (38) NS 5 visits 13 (38) 8 (62) 5 (24) 0.”
BackgroundSelf-citationRetracted: Interleukin‐1 blockade treatment decreasing cardiovascular risk
Zheng, Z., Zeng, X., Nie, X., Cheng, Y., Liu, J., Lin, X., Yao, H., Ji, C., Chen, X., Fan, J., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23246 · Cited by 20
“The possible mechanism that interleukin-1 blockade treatment decreased the risk of cardiovascular events was that it reduced the inflammatory response thereby decreasing the production of inflammatory mediators, especially the CRP. CRP as a widely used as inflammatory marker in clinical settings, it is also has been r…”
BackgroundInfluentialRetractedAutoinflammatory Diseases in Pediatrics
Hausmann, J. S., & Dedeoğlu, F. (2013) · Dermatologic Clinics · doi:10.1016/j.det.2013.04.003 · Cited by 21
Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes
Zhuang, L., Chen, J., Yu, J., Marathe, A., Sahajwalla, C., Borigini, M., Maynard, J. W., Burckart, G. J., & Wang, Y. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1302 · Cited by 22
Nishimura, K., Hara, R., Umebayashi, H., Takei, S., Iwata, N., Imagawa, T., Shimizu, M., Tomiita, M., Seko, N., Kitawaki, T., et al. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1783163 · Cited by 20
Verweyen, E. L., Pickering, A., Grom, A. A., & Schulert, G. S. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41640 · Cited by 20
Autoinflammatory Syndromes in Children
Pepper, R. J., & Lachmann, H. J. (2016) · The Indian Journal of Pediatrics · doi:10.1007/s12098-015-1985-y · Cited by 20
Self-citationCanakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment
Roccatello, D., & Alpa, M. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s69117 · Cited by 19
The Emerging Role of Biotechnological Drugs in the Treatment of Gout
Cavagna, L., & Taylor, W. J. (2014) · BioMed Research International · doi:10.1155/2014/264859 · Cited by 19
“Canakinumab is a fully human, anti-IL1β monoclonal antibody first approved for the treatment of cryopyrin associated periodic syndrome [45].”
BackgroundAutoinflammatory syndromes: Fever is not always a sign of infection
Zeft, A., & Spalding, S. J. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.11184 · Cited by 20
CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis
Hassan, M. S. (2018) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2018.2 · Cited by 30
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis
Abadie, B. Q., & Cremer, P. C. (2022) · BioDrugs · doi:10.1007/s40259-022-00537-7 · Cited by 20
“Canakinumab has not been associated with hematologic changes [46, 53, 66, 67].”
BackgroundArrowsmith, J. E., & Harrison, R. (2012) · Wiley eBooks · doi:10.1002/9781118274408.ch1 · Cited by 22
An innate interaction between IL-18 and the propeptide that inactivates its precursor form
Tsutsumi, N., Ayumi, Y., Kimura, T., Kato, Z., Fukao, T., Shirakawa, M., Ohnishi, H., & Tochio, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-42661-5 · Cited by 20
Curran, M. P. (2011) · BioDrugs · doi:10.2165/11208450-000000000-00000 · Cited by 18
Koné‐Paut, I., Quartier, P., Fain, O., Grateau, G., Pillet, P., Blay, P. L., Bonnet, F., Despert, V., Stankovic, K., Willemin, L., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.23083 · Cited by 18
Self-citationPERIODIC FEVER SYNDROMES AND OTHER INHERITED AUTOINFLAMMATORY DISEASES
Barron, K. S., Athreya, B. H., & Kastner, D. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6581-4.10043-3 · Cited by 25
Liu, Y., Jiang, X., Zhuang, S., Zhu, L., Zhu, B., Rui, K., & Tian, J. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103885 · Cited by 22
Forzano, I., Florimonte, D., Narciso, V., Canonico, M. E., Castiello, D. S., Manzi, L., Cristiano, S., Spinelli, A. M., Vallone, D. M., D’Alconzo, D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238334 · Cited by 17
“Canakinumab is a fully human monoclonal antibody that targets IL-1 β , and it has already been approved as a medical treatment in rheumatological disorders [208–210].”
Cunha, C. B., & Cunha, B. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00068-x · Cited by 17
Kuemmerle-Deschner, J. B., Kallinich, T., Henes, J., Kortus-Götze, B., Oommen, P. T., Rech, J., Krickau, T., Weller‐Heinemann, F., Horneff, G., Janda, A., et al. (2024) · RMD Open · doi:10.1136/rmdopen-2023-003890 · Cited by 17
Self-citationAutoinflammatory diseases in childhood
Sözeri, B., & Kasapçopur, Ö. (2014) · Modern Research in Inflammation · doi:10.4236/mri.2014.31002 · Cited by 17
Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood
Welzel, T., Benseler, S. M., & Kuemmerle-Deschner, J. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.516427 · Cited by 20
Self-citationIL-1β Antibody Protects Brain from Neuropathology of Hypoperfusion
Quintana, D. D., Ren, X. S., Hu, H., Corbin, D. R., Engler-Chiurazzi, E. B., Alvi, M., & Simpkins, J. W. (2021) · Cells · doi:10.3390/cells10040855 · Cited by 18
“The IL-1β antibody used is a selective IL-1β monoclonal antibody [18] and is similar to canakinumab, clinically used for a number of autoimmune and inflammatory conditions [19,20].”
MethodArnold, D. E., Chellapandian, D., & Leiding, J. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692219 · Cited by 19
Li, G., Zong, X., Cheng, Y., Xu, J., Deng, J., Huang, Y., Ma, C., & Fu, Q. (2022) · Veterinary Microbiology · doi:10.1016/j.vetmic.2022.109430 · Cited by 17
Inflammasome et interleukine 1
Jéru, I., & Amselem, S. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2010.02.013 · Cited by 21
Making anti-cytokine therapy more selective: Studies in mice
Drutskaya, M. S., Efimov, G. A., Astrakhantseva, I. V., Kruglov, A., & Nedospasov, S. A. (2016) · Cytokine · doi:10.1016/j.cyto.2016.08.022 · Cited by 17
Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition
Liu, A. Y. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.02.003 · Cited by 20
New insights into the nature of autoinflammatory diseases from mice with Nlrp3 mutations
Meng, G., & Strober, W. (2010) · European Journal of Immunology · doi:10.1002/eji.200940191 · Cited by 17
Tivantinib alleviates inflammatory diseases by directly targeting NLRP3
Huang, Y., Guo, Y., Zhou, Y., Huang, Q., Ru, Y., Luo, Y., & Xu, W. (2023) · iScience · doi:10.1016/j.isci.2023.106062 · Cited by 18
Treatment of autoinflammatory syndromes
Gattorno, M., & Martini, A. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3283404598 · Cited by 16
Calvo, C., Soler‐Palacín, P., Muñoz, R. M., Saavedra‐Lozano, J., López, J. A., Aróstegui, J. I., Blázquez‐Gamero, D., Martín‐Nalda, A., Juan, M., Méndez, M., et al. (2010) · Anales de Pediatría · doi:10.1016/j.anpedi.2010.09.022 · Cited by 16
Seki, R., Ohta, A., Niwa, A., Sugimine, Y., Naito, H., Nakahata, T., & Saito, M. K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237030 · Cited by 16
Hereditary Systemic Autoinflammatory Diseases: Therapeutic Stratification
Cınar, O. K., Putland, A., Wynne, K., Eleftheriou, D., & Brogan, P. A. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.867679 · Cited by 18
“Systemic AA amyloidosis, a life-threatening complication of SAIDs that mainly presents with renal involvement, was reported to occur in approximately 25% of CAPS patients prior to targetted treatment with IL1 blockade (52).”
BackgroundMethodInfluentialPattern Recognition Receptors in Immune Disorders Affecting the Skin
de Koning, H. D., Simon, A., Zeeuwen, P. L. J. M., & Schalkwijk, J. (2012) · Journal of Innate Immunity · doi:10.1159/000335900 · Cited by 17
Precision Therapy for the Treatment of Primary Immunodysregulatory Diseases
Chellapandian, D., Chitty-Lopez, M., & Leiding, J. W. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.04.001 · Cited by 15
Miyamoto, T., Izawa, K., Masui, S., Yamazaki, A., Yamasaki, Y., Matsubayashi, T., Shiraki, M., Ohnishi, H., Yasumura, J., Kawabe, T., et al. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42808 · Cited by 16
Ran, L., Chen, M., Ye, J., Zhang, S., Luo, Z., Bai, T., Qian, C., Zhou, Q., Shan, M., Chu, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202307224 · Cited by 17
Quantitative Analysis to Guide Orphan Drug Development
Lesko, L. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.80 · Cited by 15
Giat, E., Ben‐Zvi, I., Lidar, M., & Livneh, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073956 · Cited by 21
“It does not react with interleukin-1 alpha [103].”
BackgroundThe role of interleukin-1 in perinatal inflammation and its impact on transitional circulation
Owen, J. C., Garrick, S. P., Peterson, B. M., Berger, P. J., Nold, M. F., Sehgal, A., & Nold‐Petry, C. A. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1130013 · Cited by 19
“Other trialed strategies of blocking IL-1 [reviewed in (29)] include soluble IL-1 receptor (35), neutralizing IL-1β (36, 37) or IL-1R1-blocking antibodies (38).”
BackgroundTorices, S., Daire, L., Simon, S., Mendoza, L., Daniels, D., Joseph, J.-A., Fattakhov, N. S., Naranjo, O., Téglás, T., & Toborek, M. J. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.05.009 · Cited by 15
“Two additional IL-1R inhibitors used in pilot studies in people with cryopyrin-associated periodic syndromes [110] are rilonacept and canakinumab [109,111–113].”
Cryopyrin-assoziiertes periodisches Syndrom
Kümmerle-Deschner, J. B. (2012) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-011-0856-9 · Cited by 16
Canakinumab for treatment of cryopyrin-associated periodic syndrome
Feist, E., & Burmester, G. R. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.530653 · Cited by 15
“Efficacy and safety of ACZ885 were further investigated in a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS [20].”
BackgroundRenin-Dependent Hypertension in Mice Requires the NLRP3- Inflammasome
So, A. W. A. (2013) · Journal of Hypertension Open Access · doi:10.4172/2167-1095.1000187 · Cited by 15
“IL1 inhibition has been found to be extremely effective in the treatment of monogenic autoinflammatory disorders due to mutations of the Nlrp3 gene [30] in the treatment of MSU-crystal induced inflammation in acute gout [11] and in the treatment of other inflammatory diseases of unknown cause [15].”
The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome
van der Meer, J. W. M., & Simon, A. (2016) · Rheumatology · doi:10.1093/rheumatology/kew351 · Cited by 19
Unified Modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
Varolgüneş, Y. B., Demir, A., Erman, B., & Gül, A. (2015) · Computational and Mathematical Methods in Medicine · doi:10.1155/2015/893507 · Cited by 18
“IL-1β not only activates the fever pathway, but also causes pain sensitization and bone and cartilage destruction and activates acute phase response [38].”
BackgroundIdiopathic Pericarditis—an Autoinflammatory Disease?
Blank, N., & Lorenz, H. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0820-2 · Cited by 17
So, A. K.-L., & Busso, N. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.112508 · Cited by 15
“gene, a component of the inflammasome, in patients with a subset within the autoinflammatory syndromes (now called cryopyrin-associated periodic syndromes or CAPS) led to the idea of targeting IL1β in this disease. The results have been spectacular”
BackgroundManaging Your Patient with Gout: A Review of Treatment Options
Doghramji, P. P. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.05.2284 · Cited by 14
A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis
Wulffraat, N. M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1112377 · Cited by 14
“[20,21,25,26] Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the US Food and Drug Administration (FDA) on June 2009 and by the European Medicines Agency (EMA) in October 2009.”
BackgroundSpectrum of Genetic Autoinflammatory Diseases Presenting with Cutaneous Symptoms
Bonnekoh, H., Butze, M., Kallinich, T., Kambe, N., Kokolakis, G., & Krause, K. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3427 · Cited by 15
Blocking of interleukin-1 suppresses angiotensin II-induced renal injury
Akita, K., Isoda, K., Ohtomo, F., Isobe, S., Niida, T., Sato-Okabayashi, Y., Sano, M., Shimada, K., Iwakura, Y., & Minamino, T. (2021) · Clinical Science · doi:10.1042/cs20201406 · Cited by 14
“cryopyrin-associated periodic syndrome (CAPS) in humans [33].”
Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome
Yoshikawa, T., Kawai, M. M., Nishikomori, R., Heike, T., & Takahashi, K. A. (2013) · Clinical ophthalmology · doi:10.2147/opth.s49281 · Cited by 18
Canakinumab for the treatment of TNF-receptor associated periodic syndrome
Torre, F. L., Caparello, M. C., & Cimaz, R. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1324783 · Cited by 14
“The disease-causing gene transcript was upregulated in treatment-naïve patients with active TRAPS, compared with healthy volunteers, and then normalized with canakinumab treatment [76].”
BackgroundResultCanakinumab for the cryopyrin-associated periodic syndromes
Savic, S., & McDermott, M. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.195 · Cited by 14
“The efficacy of this drug in the treatment of CAPS is illustrated by the results of a phase III clinical trial reported by Lachmann et al”
MethodHow Safe Are Biological Agents in Pediatric Rheumatology?
Yayla, E. N. S., Yıldız, Ç., Şenol, P. E., Karaçayır, N., Yıldırım, D. G., & Bakkaloglu, S. A. (2024) · Turkish Archives of Pediatrics · doi:10.5152/turkarchpediatr.2024.23221 · Cited by 13
Karnewar, S., Karnewar, V., Deaton, R. A., Shankman, L. S., Benavente, E. D., Williams, C. M., Bradley, X., Alencar, G. F., Bulut, G. B., Kirmani, S., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320800 · Cited by 13
Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches
Vulpetti, A., Rondeau, J., Bellance, M.-H., Blank, J., Boesch, R., Boettcher, A., Bornancin, F., Buhr, S., Connor, L. E., Dumelin, C. E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00240 · Cited by 14
Innovative approaches to clinical development and trial design.
Orloff, J. J., & Stanski, D. R. (2011) · PubMed · doi:10.4415/ann_11_01_03 · Cited by 13
The inflammasome in biomaterial‐driven immunomodulation
Vasconcelos, D. P., Águas, A. P., & Barbosa, J. N. (2022) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3361 · Cited by 14
“The blocking of IL‐1 leads to a rapid and continual reversal of daily symptoms, diminishing long‐term disease consequences (Hoffman, 2009; Lachmann et al., 2009; Sib- ley et al., 2012).”
BackgroundThe clinical role of anakinra in the armamentarium against familial Mediterranean fever
Parlar, K., Ates, M. B., Egeli, B. H., & Uğurlu, S. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2299230 · Cited by 15
Jacobs, Z., & Ciaccio, C. E. (2010) · Current Allergy and Asthma Reports · doi:10.1007/s11882-010-0141-z · Cited by 16
Therapies in Development for Non-Infectious Uveitis
Sadiq, M. A., Agarwal, A. K., Hassan, M., Afridi, R., Sarwar, S., Soliman, M. K., Diana, V., & Nguyen, Q. D. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150731103847 · Cited by 13
Cattalini, M., Soliani, M., Lopalco, G., Rigante, D., & Cantarini, L. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1466-y · Cited by 13
Periodic fevers and autoinflammatory syndromes in childhood
Ostring, G. T., & Singh‐Grewal, D. (2016) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.13326 · Cited by 13
Lifelong Immune Modulation Versus Hematopoietic Cell Therapy for Inborn Errors of Immunity
Cooper, M. A., Zimmerman, O., Nataraj, R., & Wynn, R. F. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.11.055 · Cited by 14
Analysis of clinical trials with biologics using dose–time‐response models
Lange, M. R., & Schmidli, H. (2015) · Statistics in Medicine · doi:10.1002/sim.6551 · Cited by 14
An Overview of Infectious Complications in Children on New Biologic Response-Modifying Agents
Abinun, M. (2010) · Pediatric Health · doi:10.2217/phe.10.57 · Cited by 12
Gedik, K. C., Arıcı, Z. S., Cınar, O. K., García‐Bournissen, F., Romano, M., & Demirkaya, E. (2024) · Pediatric Drugs · doi:10.1007/s40272-023-00615-5 · Cited by 13
Haviv, R., Zeitlin, L., Moshe, V., Ziv, A., Rabinowicz, N., Benedetti, F. D., Prencipe, G., Matteo, V., Cunto, C. L. D., Hsiao, E. C., et al. (2024) · Rheumatology · doi:10.1093/rheumatology/keae255 · Cited by 12
Lipsker, D. M., & Lenormand, C. (2012) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2012.03.012 · Cited by 13
Pediatric hereditary autoinflammatory syndromes
de Jesus, A. A., Oliveira, J. B., Hilário, M. O. E., Terreri, M. T. R. A., Fujihira, E., Watase, M., Carneiro-Sampaio, M. M. S., & Silva, C. A. (2010) · Jornal de Pediatria · doi:10.1590/s0021-75572010000500003 · Cited by 16
Successful Management of Cryopyrin-Associated Periodic Syndrome With Canakinumab in Infancy
Kanariou, M. G., Tantou, S., Varela, I., Raptaki, M., Petropoulou, C., Nikas, I., & Valari, M. (2014) · PEDIATRICS · doi:10.1542/peds.2013-3185 · Cited by 13
Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain
Yang, C., Delproposto, J., Chinnaswamy, K., Brown, W. C., Wang, S., Stuckey, J. A., & Wang, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146522 · Cited by 13
“They include FDA-approved Anakinra (an analog of the IL-1R antagonist, IL-1Ra)[17] and Canakinumab (an anti-IL-1βmonoclonal antibody)[18] for treating rheumatoid arthritis and cryopyrin-associated periodic syndromes.”
BackgroundConfounding role of tumor necrosis factor in cryopyrin-associated periodic syndromes
Banoth, B., & Sutterwala, F. S. (2017) · Journal of Clinical Investigation · doi:10.1172/jci98322 · Cited by 12
Monogenic autoinflammatory disorders: beyond the periodic fever
Moghaddas, F. (2019) · Internal Medicine Journal · doi:10.1111/imj.14414 · Cited by 13
Phenotype variability of autoinflammatory disorders in the pediatric patient: A pictorial overview
Rigante, D. (2020) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12406 · Cited by 13
(2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.010 · Cited by 12
Applying Physiological and Biochemical Concepts to Optimize Biological Drug Development
Lowe, P. J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.302 · Cited by 12
Regulated cell death in chronic kidney disease: current evidence and future clinical perspectives
Giuliani, K. T. K., Adams, B. C., Healy, H. G., & Kassianos, A. J. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1497460 · Cited by 11
Chronic recurrent wheals – If not chronic spontaneous urticaria, what else?
Bonnekoh, H., Krause, K., & Kolkhir, P. (2023) · Allergologie select · doi:10.5414/alx02375e · Cited by 18
“Concomitant diseases such as hearing loss or amyloidosis can also be positively influenced by the treatment [16, 17].”
BackgroundAlcohol-associated liver disease: Emerging therapeutic strategies
Mullish, B. H., & Thursz, M. R. (2024) · Hepatology · doi:10.1097/hep.0000000000000986 · Cited by 14
“[62] It has also been used to address the inflammatory component of atherosclerosis resulting in reduced incidence of cardiac events after myocardial infarction.”
Canakinumab in pediatric rheumatic diseases
Wulffraat, N. M., & Woo, P. M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.778239 · Cited by 11
“With the development of canakinumab which is specifically targeted to IL-1b (Box 1), clinical trials have shown impressive disease suppression [5,10] and is now licensed by the Food and Drug Administration (FDA) for the treatment of CAPS.”
BackgroundMarsaud, C., MARIE, I., & Koné‐Paut, I. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.131291 · Cited by 11
Treatment of adult hyper-IgD syndrome with canakinumab
Curtis, C. D., & Fox, C. C. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.05.020 · Cited by 11
ter Haar, N. M., Jansen, M. H. A., Frenkel, J., & Vastert, S. J. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108538 · Cited by 11
Overview of the rarest causes of fever in newborns: handy hints for the neonatologist
Rose, D. U. D., Coppola, M. G., Gallini, F., Maggio, L., Vento, G., & Rigante, D. (2020) · Journal of Perinatology · doi:10.1038/s41372-020-0744-8 · Cited by 11
“More recently, canakinumab, a fully human anti-IL-1 monoclonal antibody that selectively blocks IL-1, has shown a prompt and brilliant clinical efficacy if administered every 4–8 weeks [23].”
BackgroundAutoinflammatorische Syndrome/Fiebersyndrome
Schedel, J., Bach, B., Kümmerle-Deschner, J. B., & Kötter, I. (2011) · Der Hautarzt · doi:10.1007/s00105-010-2124-3 · Cited by 11
Metadata
- Authors
- Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N.
- Affiliations
- University College London (GB)
- Universitätsklinikum Tübingen (DE)
- University of California, San Francisco (US)
- Université de Lille (FR)
- Hôpital Necker-Enfants Malades (FR)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-06-04
- Volume
- 360
- Issue
- 23
- Pages
- 2416-2425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149374693
- Cited by
- 869
- References
- 19
- Citations by year
- 2026: 23 · 2025: 30 · 2024: 31 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 53 · 2019: 56 · 2018: 34 · 2017: 38 · 2016: 55 · 2015: 67 · 2014: 50 · 2013: 66 · 2012: 73
- FWCI
- 35.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- canakinumab, cryopyrin-associated periodic syndromes, IL-1β, interleukin-1 receptor antagonist, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, disease flares, C-reactive protein, serum amyloid A, infection risk, urosepsis, vertigo, treatment withdrawal
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Adolescent, Adult, Aged, Antibodies, Monoclonal, Carrier Proteins, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Familial Mediterranean Fever, Interleukin-1beta, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.